Novo Nordisk's Semaglutide Improves Liver Health in Non-Obese MASH Patients in Trial Analysis

• Novo Nordisk will present new liver research on Wegovy and investigational efruxifermin at The Liver Meeting, November 5-9, 2026, in Denver.
• A post-hoc analysis of the phase 3 ESSENCE trial found semaglutide improved liver health in non-obese participants with MASH.
• Analyses from the phase 2b SYMMETRY trial showed efruxifermin improved liver scarring in participants with MASH cirrhosis, including those with cardiometabolic conditions.
• The PLATINUM-Truveta retrospective study will present comparisons of semaglutide and resmetirom on liver enzymes and cardiometabolic markers in routine clinical practice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.